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Background: Reliable, noninvasive approaches to the diagnosis of pulmonary hypertension
in idiopathic pulmonary fibrosis are needed. We tested the hypothesis that the forced vital
capacity to diffusing capacity ratio and room air resting pulse oximetry may be combined
to predict mean pulmonary artery pressure (MPAP) in idiopathic pulmonary fibrosis.
Methods: Sixty-one idiopathic pulmonary fibrosis patients with available right-heart
catheterization were studied. We regressed measured MPAP as a continuous variable on
pulse oximetry (SpO2) and percent predicted forced vital capacity (FVC) to percent-
predicted diffusing capacity ratio (% FVC/% DLco) in a multivariable linear regression
model.
Results: Linear regression generated the following equation: MPAP ¼ 11.9+0.272
SpO2+0.0659 (100SpO2)2+3.06 (% FVC/% DLco); adjusted R2 ¼ 0.55, po0.0001.
The sensitivity, specificity, positive predictive and negative predictive value ofElsevier Ltd. All rights reserved.
gas; CI, confidence interval; DE, Doppler echocardiography; DLco, diffusing capacity for carbon
FEV1, forced expiratory volume in 1 s; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis;
mean pulmonary artery pressure; NPV, negative predictive value; PH, pulmonary hypertension; PaO2,
lmonary function tests; PPV, positive predictive value; RHC, right-heart catheterization; RV, residual
pressure from echocardiography; SpO2, resting room air pulse oximetry; TLC, total lung capacity; VA,
istance.
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D.A. Zisman et al.2154model-predicted pulmonary hypertension were 71% (95% confidence interval (CI): 50–89%),
81% (95% CI: 68–92%), 71% (95% CI: 51–87%) and 81% (95% CI: 68–94%).
Conclusions: A pulmonary hypertension predictor based on room air resting pulse
oximetry and FVC to diffusing capacity ratio has a relatively high negative predictive
value. However, this model will require external validation before it can be used in clinical
practice.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Pulmonary hypertension (PH) is common in patients with
idiopathic pulmonary fibrosis (IPF) and its presence has a
significant adverse impact on survival.1,2 Echocardiography
is commonly used to diagnose PH; however, echocardiogra-
phy is frequently inaccurate in patients with interstitial lung
disease (ILD).3 Right-heart catheterization (RHC) is the gold
standard for diagnosis of PH in IPF patients.3,4 However, it is
an invasive method with significant risks for complications.
Noninvasive approaches to the diagnosis of PH in IPF
would improve patient safety and reduce cost. The ability to
predict which IPF patients have PH using noninvasive
measures could guide the selection of patients for RHC to
confirm its presence.
In ILD patients, the diffusing capacity for carbon
monoxide (DLco) falls because of fibrosis, emphysema and
pulmonary vascular disease.5,6 In these patients, a reduction
in DLco out of proportion to the reduction in lung volumes
might indicate underlying pulmonary vascular disease. For
instance, in patients with scleroderma, when there is a
mixture of both fibrosis and pulmonary vasculopathy, the
forced vital capacity (FVC) is moderately decreased but the
DLco is even lower and the FVC to DLco ratio is often greater
than 1.8.7–12 We therefore hypothesized that a high FVC/
DLco ratio might be a marker for increased pulmonary artery
pressures in IPF.
Chronic hypoxia causes pulmonary vasoconstriction
through a diversity of actions on pulmonary artery endothe-
lium and smooth muscle cells, including downregulation of
endothelial nitric oxide synthase and reduced production of
the voltage-gated potassium channel alpha subunit.13,14
Although initially reversible, the pathologic changes induced
by hypoxia-induced vasoconstriction ultimately result in
irreversible vascular remodeling.15,16
The independent associations of FVC/DLco ratio and
chronic hypoxia with PH in ILD patients, raise the possibility
that these factors may be combined to improve the
prediction of PH in IPF patients.
Methods
Study sample
We retrospectively reviewed the medical records of all IPF
patients who were seen at our institution between July 1999
and June 2006. During their initial visit, all patients
provided written informed consent to use their clinical and
demographic information for research purposes. All patientsmet accepted diagnostic criteria for IPF and the majority
(61%) had histopathologic evidence of usual interstitial
pneumonia.17 Two hundred and ninety-eight IPF patients
were candidates for inclusion in this study. To be included in
the study, participants had to have had RHC and have
pulmonary function test (PFT) and resting pulse oximetry
data while breathing room air (SpO2) within 1 month of the
RHC. Fifty five patients met this entry criterion. Six other
patients had RHC and PFTs and were known to require
supplemental oxygen; however, their actual SpO2 was not
available. We included these six patients and used the
imputed value of 85% for their SpO2. We used 85% because it
was the mean SpO2 in the 15 patients requiring supple-
mental oxygen who had measurements of SpO2. Thus, our
study sample consisted of 61 patients.
Measurements
RHC data included measurements of pulmonary arterial
pressures with the patient at rest. We defined PH as a
resting mean pulmonary artery pressure (MPAP) of
425mmHg.18
SpO2 measurements were conducted in agreement with a
clinical protocol: after at least 5min of rest, SpO2 was
measured on room air. All SpO2 measurements were done
with the same oximeter (Digital Handheld Pulse Oximeter,
Nonin Medical, Inc.).
Standard methodology was used for obtaining PFT, ABG,
6MWD, and RVSP from Doppler echocardiography.19–25
Statistical analysis
We compared patients in the study sample with those
excluded with respect to the variables of interest, using
standard tests for comparing means (Student’s t-test),
medians (Wilcoxon rank-sum test) and proportions (Chi-
square test or the Fisher’s exact test, if cell sizes are small).
We regressed the MPAP (obtained from RHC) as a
continuous variable on SpO2 and % FVC/% DLco, both as
continuous predictors in a multivariable linear regression
model. Examination of the model residual indicated that the
model underestimated MPAP in patients with high MPAP and
overestimated MPAP in patients with low MPAP. We therefore
added a quadratic term (100SpO2)2 to the model. Given the
moderately small sample size, no attempt was made to
further refine the model, to avoid overly optimistic results.26
We compared this final model’s prediction ability with
alternate models that included other predictors or alternate
predictors. MPAP prediction ability was assessed by model R2
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the following variables to the model: age, gender, RVSP,
6MWD and % DLco/% VA. Further, we tried replacing SpO2 in
the model by PaO2 and replacing % FVC/% DLco by DLco
(absolute and % predicted).
The final model was internally validated using boot-
strapping, which is superior to methods of validation by
sample splitting.27,28 Using RHC-defined PH as the gold
standard, we calculated the sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV)
of diagnosing PH based on model-predicted MPAP425mmHg
in 1000 bootstrapped samples, and the empirical bootstrap
distribution of each measure was used to determine the 95%
confidence interval (CI) for that measure. Since some
clinicians may be interested in a test with maximum
sensitivity, so as to minimize the chance of missing a case
of PH, we examined several alternate cut points for
diagnosing PH from the model-predicted MPAP, using RHC-
defined PH as the gold standard, and determined the cutoff
that maximizes sensitivity with the least compromise in
specificity.Table 1 Descriptive statistics for major characteristics.
Characteristic Mean (SD)
or %
Mean (SD)
or %
p-Value
Study
sample
(n ¼ 61)
Excluded
(n ¼ 237)
Age (years) 62.6 (8.7) 67.4 (9.6) 0.0523
Males (%) 57.4 64.1 0.3303
Race (%) 0.7373
Caucasian 80.3 76.6
Hispanic 14.8 14.9
Othery 4.9 8.5
FVC (L) 2.0 (0.7) 2.4 (0.9) o0.0001
% FVC predicted 53.7 (16.5) 65.9 (18.7) o0.0001
DLCO (ml/
mmHg/min)
7.9 (3.6) 9.9 (4.3) 0.0004
% DLCO
predicted
33.3 (14.8) 42.8 (18.8) o0.0001
% FVC/% DLCO 1.8 (0.9) 1.8 (1.1) 0.9834
SpO2 (%) 90.1 (4.9) 92.9 (4.8) 0.0533
PaO2 (mmHg) 62.1 (12.0) 66.4 (15.1) 0.0532
MPAP (mmHg) 25.5 (9.6) 29.2 (11.0)z 0.1002
Age available in 237 of 237 patients; race available in 235
of 237; forced vital capacity (FVC, absolute and % predicted)
available in 219 of 237; diffusing capacity (DLCO, absolute and
% predicted) available in 210 of 237; FVC percent-predicted/
DLCO percent-predicted ratio (% FVC/% DLCO) available in 210
of 237; resting room air pulse oximetry (SpO2%) available in
188 of 237; resting room air arterial blood partial pressure of
oxygen (PaO2) available in 65 of 237; mean pulmonary artery
pressure (MPAP) available in 36 of 237.
yIncludes Asian and African-American. SD, standard devia-
tion.
zThese subjects were excluded from the study sample
because their RHC was not performed within 1 month of the
PFT (see Methods).We calculated the sensitivity, specificity, PPV and NPV of
diagnosing PH based on echocardiography (RVSP4
40mmHg),29 using RHC-defined PH as the gold standard
(MPAP425mmHg). We also determined the cutoff that
maximizes sensitivity with the least compromise in
specificity.
All tests were two-tailed, and p values of o0.05 were
assumed to represent statistical significance. All statistical
analyses were performed using SAS version 9.1 (SAS Institute
Inc., Cary, NC, USA).
Results
The study sample (n ¼ 61) was systematically different from
the 237 patients who were excluded as shown in Table 1.
Patients in the study sample were younger with more
advanced IPF. As shown in Table 2, age, gender and FVC did
not differ between those with or without PH. A trend
towards lower absolute DLco, and higher % FVC/% DLco was
seen in patients with PH. % DLco, SpO2 and PaO2 were
significantly lower in those with PH. There were strong
correlations in the expected directions between MPAP and
the primary predictors (Table 3). There were also strong
correlations in the expected directions between MPAP and
other variables (Table 4): RVSP, PaO2, 6MWD, % DLco/% VA
and % DLco. There was no correlation between MPAP and
FVC, FEV1, FEV1/FVC, TLC or the RV; data not shown.
Linear regression of MPAP on SpO2 (linear and quadratic
terms) and % FVC/% DLco generated the following equation
for MPAP in mmHg:
MPAP ¼  11:9þ 0:272 SpO2 þ 0:0659 ð100 SpO2Þ2
þ 3:06 ð%FVC=%DLcoÞ. ð1ÞTable 2 Patient characteristics based on the presence
or absence of PH by RHC.
Characteristic Mean (SD)
or %
Mean (SD)
or %
p-Value
MPAPp25
(n ¼ 37)
MPAP425
(n ¼ 24)
Age (years) 65.6 (7.8) 63.7 (10.1) 0.7294
Males (%) 62 50 0.3481
FVC (L) 2.0 (0.6) 2.0 (0.9) 0.5043
% FVC predicted 53.5 (14.2) 54.1 (19.8) 0.9531
DLCO (ml/
mmHg/min)
8.2 (3.1) 7.3 (4.3) 0.0606
% DLCO
predicted
35.4 (13.4) 30.1 (16.6) 0.0332
% FVC/% DLCO 1.7 (0.8) 2.0 (0.9) 0.0906
SpO2 (%) 93.1 (3.6) 87.7 (5.1) o0.0001
PaO2 (mmHg) 68.9 (11.4) 57.8 (9.5) 0.0010
MPAP (mmHg) 20.0 (3.8) 33.9 (9.8) o0.0001
FVC, forced vital capacity; DLCO, diffusing capacity; MPAP,
mean pulmonary artery pressure; PaO2, resting room air
partial pressure of oxygen; SpO2, resting room air pulse
oximetry.
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in Table 5. This model explained 55% of the variance of MPAP
(adjusted R2 ¼ 0.55, po0.0001). A scatter plot of predicted
versus measured MPAP is shown in Fig. 1. Sequential and
partial sums of squares associated with the primary
predictors demonstrated that SpO2 provided the majority
of the predictive information.Table 3 Pearson correlation coefficients between the
mean pulmonary artery pressure (MPAP) of the primary
predictors.
Variable n r p-Value
SpO2 (%) 61 0.67 o0.0001
% FVC/% DLCO 61 0.30 0.02
% FVC, percent predicted forced vital capacity; % DLCO,
percent predicted diffusing capacity; SpO2, resting room air
pulse oximetry.
p-Value for test of zero correlation.
Table 4 Pearson correlation coefficients between the
mean pulmonary artery pressure (MPAP) and other
potential predictor variables.
Variable n r p-Value
DLCO/% VA predicted 47 0.44 0.002
% DLCO predicted 61 0.30 0.02
6-min walk distance (m)y 26 0.55 0.003
Resting room air PaO2 (mmHg) 55 0.50 o0.0001
DE-estimated RVSP (%) 33 0.72 o0.0001
FVC, forced vital capacity; DLCO, diffusing capacity; PaO2,
arterial blood partial pressure of oxygen; DE, Doppler
echocardiography; RVSP, right ventricular systolic pressure;
VA, alveolar volume.
p-Value for test of zero correlation.
yWhile breathing room air.
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Figure 1 MPAP, mean pulmonary artery pressure; SpO2, resting ro
vital capacity/percent predicted diffusing capacity ratio.We compared the prediction ability (using R2) of the
model in Eq. (1) with alternate models. Regression
parameter estimates for the primary predictors changed
by o10% when potential confounders age and gender were
added to the model (data not shown). Moreover, model fit
did not improve with the addition of these demographic
characteristics to the model (adjusted R2 changed from 0.55
to 0.53). We added RVSP, 6MWD and % DLco/% VA, as
additional predictors to the model. Addition of these
variables did not improve model fit. Further, we tried PaO2
in place of SpO2 and DLco (absolute and % predicted) in place
of % FVC/% DLco. Neither improved model fit (data not
shown).
To assess the impact of imputing 85% for SpO2 in the six
patients missing the measurement, we added a 0/1 indicator
variable that flagged those with imputed SpO2; the R
2 did
not change and the regression parameter estimate for the
indicator variable was 1.5 (p ¼ 0.6), indicating that MPAP in
these patients was not biased by the imputation. We then
replaced the measured SpO2 in everyone whose measured
value was p88% and in everyone who was missing the
measurement because he/she was on supplemental oxygen
by a constant value of 88% in the model; the R2 fell to 0.29,35 40 45 50 55 60 65
ry Artery Pressure
9∗(100 - SpO2)
2 + 3.06∗(%FVC/%DLco)
om air pulse oximetry; % FVC/% DLco, percent predicted forced
Table 5 Parameter estimates for MPAP by candidate
predictors.
Variable Parameter
estimate
95% CI p-Value
Intercept 11.93 115.89 to
92.03
0.82
Resting room
air SpO2 (%)
0.27 0.81 to 1.35 0.62
(100SpO2)2 0.07 0.02 to 0.11 0.004
% FVC/% DLCO 3.06 1.08 to 5.04 0.003
% FVC, percent predicted forced vital capacity; % DLCO,
percent predicted diffusing capacity; SpO2, pulse oximetry.
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Table 6 Performance of the model (compared to conventional echocardiogram) in establishing or excluding a diagnosis of
pulmonary hypertension (PH), using right-heart catheterization (RHC) as the gold standard.
Sensitivity (95% CI) Specificity (95% CI) Positive predictive
value (95% CI)
Negative predictive
value (95% CI)
Model-based PH
diagnosis
71% (50–89%) 81% (68–92%) 71% (51–87%) 81% (68–94%)
Echo-based PH
diagnosis
76% (50–92%) 38% (16–64%) 56% (35–76%) 60% (27–86%)
PH, pulmonary hypertension; RHC, right-heart catheterization.
*Pulmonary hypertension was considered to be present when the MPAP was greater than 25mmHg.
Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis 2157implying that the extent of desaturation below 88% adds
valuable information to the model.
The ability of the model to predict PH (using predicted
MPAP425mmHg) in the study sample was examined
(Table 6). To internally validate Eq. (1), we examined the
sensitivity, specificity, PPV and NPV of the model-predicted
PH in 1000 bootstrapped samples, and used the 2.5th and
97.5th percentile values of the resulting distributions to
construct 95% CI. With predicted MPAP425mmHg as the
definition of model-predicted PH, the sensitivity, specificity,
PPV and NPV of model-predicted PH (together with boot-
strapped 95% CI) were 71% (95% CI: 50–89%), 81% (95%
CI: 68–92%), 71% (95% CI: 51–87%) and 81% (95% CI: 68–94%).
We also examined the performance of the predictor with a
more liberal definition of model-predicted PH: predicted
MPAP421mmHg; sensitivity and NPV both increased to 100%
and specificity and PPV fell to 40% and 52%, respectively.
Estimation of RVSP by echocardiography was possible in
33 (54%) of the 61 patients. The sensitivity, specificity, PPV
and NPV of echocardiography-diagnosed PH (RVSP440
mmHg) were 76% (95% CI, 50–92%), 38% (95% CI, 16–64%),
56% (95% CI, 35–76%) and 60% (95% CI, 27–86%), respectively.
We determined the cutoff that maximizes sensitivity
with the least compromise in specificity. Using RVSP437
mmHg, sensitivity and NPV increased to 93% and 75%,
respectively, and specificity and PPV fell to 17% and 48%,
respectively.Discussion
We tested the hypothesis that the FVC/DLco ratio and SpO2
may be combined to predict MPAP in IPF patients. Sequential
and partial sums of squares associated with the primary
predictors demonstrated that SpO2 provided the majority of
the predictive information. When we replaced measured
SpO2 in everyone who required supplemental oxygen by a
constant value of 88%, the R2 fell to 0.29, implying that the
actual extent of desaturation below 88% adds valuable
information to the model. In our study, DLco did not
contribute to MPAP prediction above and beyond SpO2;
however, the FVC/DLco did. Our finding that if not normal-
ized by FVC, DLco adds no additional information beyond
SpO2 is consistent with findings in patients with scleroderma
and pulmonary fibrosis.7–12 Investigators examined DLco
relative to lung volume in patients with scleroderma as a
way of identifying patients with disproportionately low DLcowho had PH. In their series, this ratio was greater than 1.4 in
70% of patients with PH.10 Similarly, in a study of patients
with scleroderma who had moderate fibrosis with PH out of
proportion to the degree of fibrosis,7 the FVC was
moderately decreased but the DLco was even lower and
the ratio was often greater than 1.8. We used FVC/DLco as a
way of quantifying disproportionately low DLco and identify-
ing patients with pulmonary vascular disease, and found
that this ratio added valuable information to the prediction
of MPAP.
The prediction model will require external validation
before it can be used to guide clinical decision making
regarding whether or not to proceed to RHC. The model’s
high NPV is not because of low prevalence of PH in our study
sample. In fact, PH was present in 41% of our patients, a
figure comparable to that reported by others.1,30 If
externally validated, the model’s high NPV could be used
clinically to avoid RHC in selected patients (e.g., before
a surgical lung biopsy, which is always safer in non-PH
patients, or as exclusion criteria in clinical trials evaluating
vasodilator therapy in patients with IPF). Using a predicted
MPAP425mm as the cut point to select individuals for
RHC would miss one in five cases with PH, a figure
unacceptable to many clinicians; however, using a lower
threshold such as predicted MPAP421mm to select indivi-
duals for RHC nearly eliminates the possibility of missing an
individual with PH at the cost of having to do RHC in a few
more individuals.
The performance characteristics of echo-based diagnosis
of PH in a homogeneous sample of IPF patients have not
been reported previously. Our data show that DE-estimated
RVSP predicted PH in IPF patients with 76% sensitivity, 38%
specificity, 56% PPV and 60% NPV. In a separate study,
echocardiography predicted PH in patients with various ILD
with 85% sensitivity, 17% specificity, 60% PPV and 44% NPV.3
When compared with echocardiography, our model’s speci-
ficity and NPV are substantially better. More importantly, our
model could allow the prediction of MPAP and PH in almost
every IPF patient while echocardiographic estimation of
RVSP is possible in only 44–54% of patients.3 Nevertheless,
echocardiography provides additional important information
(other than RVSP) such as right atrial size, right ventricular
size and function, which may be pertinent to the identifica-
tion of PH. The predictive ability of these measures is the
topic of an ongoing study.
In a previous study, the need for supplemental oxygen
together with a DLcoo40% identified the presence of PH in
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patients; however, the predicted prevalence of PH was
15.2%, suggesting that a prediction based on DLco alone and
the need for supplemental oxygen (yes/no) would miss half
the PH cases. By contrast, both the predicted and observed
prevalence of PH in our study were 41%. In our study, DLco
did not contribute to MPAP prediction above and beyond
SpO2; however, the FVC/DLco ratio did. Furthermore, the
extent of desaturation below 88% added valuable informa-
tion to the model. Our study validates the notion that the
need for supplemental oxygen together with a reduced DLco
identifies the presence of PH in IPF patients, and it improves
on it by using the extent of desaturation in place of need for
oxygen (yes/no) and the FVC/DLco ratio in place of DLco to
increase sensitivity and NPV.
There are limitations of our study. This was a retro-
spective review of patients evaluated at a single center.
Most of our patients underwent evaluation for lung
transplantation, reflecting the presence of younger patients
with more advanced IPF. In clinical practice, RHC are almost
exclusively performed as part of the pre-transplant evalua-
tion in advanced IPF patients. Unfortunately, RHC data are
not available from early IPF patients because there are no
clinical indications to catheterize these patients. Prospec-
tive work including patients with the complete spectrum of
disease severity will be required to avoid selection bias from
studying only those with more advanced illness. However,
this study and others have found that PH is more prevalent
in patients with severe IPF defined by a reduced DLco
1,2,31;
hence, this population is the one in whom identification
of PH is more critical. Since the RHC in this study was
not done with exercise, we could not assess for exercise-
induced PH. More importantly, our model may not be
reproducible in other data sets; the prediction model will
require external validation before it can be used to guide
clinical decision making regarding whether or not to proceed
to RHC.
In summary, a predictor based on SpO2 and FVC/DLco has a
high NPV, which compares favorably to available noninvasive
diagnostic assessments of PH in IPF. In our study, DLco alone
did not contribute to MPAP prediction above and beyond
SpO2; however, the FVC/DLco did. Furthermore, the extent
of desaturation below 88% added valuable information to
the model. Using the extent of desaturation in place of need
for oxygen (yes/no) and the FVC/DLco ratio in place of DLco
improved sensitivity and NPV considerably. This MPAP and PH
prediction model will require external validation before it
can be used in clinical practice.
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